We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Galera Therapeutics Inc | NASDAQ:GRTX | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.145 | 0.1362 | 0.1363 | 0 | 00:00:00 |
From Jan 2023 to Jan 2025
Adriano Marchese
Shares in Galera Therapeutics were halted from premarket trading on Tuesday after the Food and Drug Administration said the company needs an additional Phase 3 trial for its treatment radiotherapy-induced severe oral mucositis.
The stock closed Monday at 21 cents on the Nasdaq exchange, down about 86% for the year to date.
The clinical-stage biopharmaceutical company said it received the official FDA meeting minutes in which the agency reiterated the need for another trial of avasopasem to support the resubmission of Galera's new drug application.
Galera also decided to halt a Phase 2b trial of rucosopasem manganese, which aimed to treat locally advanced pancreatic cancer, as well as a Phase 1/2 trial of the same drug to treat nonsmall cell lung cancer.
Galera said this decision will allow it to better conserve cash while it continues to assess potential strategic alternatives.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
October 31, 2023 07:54 ET (11:54 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Galera Therapeutics Chart |
1 Month Galera Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
